/*
-- Query: SELECT * FROM avella.drug
-- Date: 2017-07-03 23:23
*/
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (1,'AVINZA','',NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (2,'BUTRANS','<ul>	<li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li>	<li>BUTRANS doses of 7.5, 10, 15, and 20 mcg/hour are only for use in patients who are opioid experienced and in whom tolerance to an opioid of comparable potency has been established. Patients who are opioid-experienced are those receiving, for one week or longer, daily opioid doses up to 80 mg/day of oral morphine or an equianalgesic dose of another opioid.</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals .</li>	<li>Do not abruptly discontinue BUTRANS in a physically dependent patient.</li></ul>>br>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.<br><ul>	<li>For opioid-naïve patients, initiate treatment with a 5 mcg/hour patch.</li>	<li>Instruct patients to wear BUTRANS for 7 days and to wait a minimum of 3 weeks before applying to the same site.</li>	<li>Do not abruptly discontinue BUTRANS in a physically dependent patient.</li></ul>','Transdermal system: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour, and 20 mcg/hour.','<ul>	<li><ul>	<li>Significant respiratory depression</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus</li>	<li>Hypersensitivity to buprenorphine</li></ul></li></ul>',' <ul>	<li><u>Life Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</u>: Monitor closely, particularly during initiation and titration.</li>	<li><u>Adrenal Insufficiency</u>: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li><u>Risk of Prolonged QTc Interval</u>: Avoid in patients with Long QT Syndrome, family history of Long QT Syndrome, or those taking Class IA or Class III antiarrhythmic medications.</li>	<li><u>Hypotension</u>: Monitor during dose initiation and titration. Avoid use of BUTRANS in patients with circulatory shock</li>	<li><u>Risks of Use in Patients with Increased Intracranial Cranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</u>: Monitor for sedation and respiratory depression. Avoid use of BUTRANS in patients with impaired consciousness or coma.</li></ul> ','Most common adverse reactions (? 5%) include: nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash.','<ul>	<li><ul>	<li><u>Benzodiazepines</u>: May increase buprenorphine-induced respiratory depression. Monitor patients on concurrent therapy closely.</li>	<li><u>CYP3A4 Inhibitors/Inducers</u>: Initiating CYP3A4 inhibitors or discontinuing CYP3A4 inducers may result in an increase in buprenorphine plasma concentrations. Closely monitor patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers for respiratory depression.</li>	<li><u>Serotonergic Drugs</u>: Concomitant use may result in serotonin syndrome. Discontinue BUTRANS if serotonin syndrome is suspected.</li>	<li><u>Mixed Agonist/Antagonist Analgesics</u>: Avoid use with BUTRANS because they may reduce analgesic effect of BUTRANS or precipitate withdrawal symptoms.</li></ul></li></ul>','<ul>	<li><u>Pregnancy</u>: May cause fetal harm.</li>	<li><u>Lactation</u>: Not recommended .</li>	<li><u>Hepatic Impairment</u>: Consider use of an alternate analgesic that may permit more flexibility in dosing.</li></ul>',1,1,'https://butrans.com/',NULL,1,'http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (3,'DOLOPHINE',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (4,'EMBEDA','<ul>	<li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li>	<li>EMBEDA 100 mg/4 mg capsules, a single dose greater than 60 mg/2.4 mg, or a total daily dose greater than 120 mg/5 mg are only for patients in whom tolerance to an opioid of comparable potency is established. </li>	<li>Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg of morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg of oral oxycodone per day, 8 mg of oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.</li>	<li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li>	<li>Instruct patients to swallow EMBEDA capsules intact, or to sprinkle the capsule contents on applesauce and immediately swallow without chewing.</li><li>Instruct patients not to cut, break, crush, dissolve, or chew the pellets in the capsule to avoid the risk of release and absorption of a potentially fatal dose of morphine, and to avoid release of sequestered naltrexone that could precipitate opioid withdrawal.</li>	<li>For opioid-naïve and opioid non-tolerant patients, initiate with 20 mg/0.8 mg capsules (morphine sulfate/naltrexone hydrochloride) orally every 24 hours.</li>	<li>Do not abruptly discontinue EMBEDA in a physically dependent patient.</li></ul>','Extended-release capsules (morphine sulfate/naltrexone hydrochloride): 20 mg/0.8 mg, 30 mg/1.2 mg, 50 mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, 100 mg/4 mg','<ul>	<li>Significant respiratory depression</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment</li>	<li>Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus</li>	<li>Hypersensitivity to morphine or naltrexone</li></ul>','<ul>	<li><ul>	<li><u>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, achectic, or Debilitated Patients</u>: Monitor closely, particularly during initiation and titration.</li>	<li><u>Adrenal Insufficiency</u>: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li><u>Severe Hypotension</u>: Monitor during dosage initiation and titration. Avoid use of EMBEDA in patients with circulatory shock.</li>	<li><u>Risk of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury or Impaired Consciousness</u>: Monitor for sedation and respiratory depression. Avoid use of EMBEDA in patients with impaired consciousness or coma.</li></ul></li></ul>','Most common adverse reactions (>10%): constipation, nausea, and somnolence','<ul>	<li><u>erotonergic Drugs</u>: Concomitant use may result in serotonin syndrome. Discontinue EMBEDA if serotonin syndrome is suspected.</li>	<li><u>Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</u>: Avoid use with EMBEDA because they may reduce analgesic effect of EMBEDA or precipitate withdrawal symptoms.</li></ul>','<ul>	<li><u>Pregnancy</u>: May cause fetal harm.</li>	<li><u>Lactation</u>: Not recommended.</li></ul>',1,1,'http://www.embeda.com/','EMBEDA is a combination opioid agonist/opioid antagonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.<u>Limitations of Use</u><ul>	<li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve EMBEDA for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li>	<li>EMBEDA is not indicated as an as-needed (prn) analgesic.</li></ul>',1,'http://labeling.pfizer.com/showlabeling.aspx?id=694');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (5,'EXALGO','<ul>	<li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li>	<li>For once daily administration IN OPIOID-TOLERANT PATIENTS. (2.1)</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.</li>	<li>Individualize dosing based on the severity of pain, patients response, prior analgesic experience, and risk factors for addiction, abuse and misuse. (2.3)</li>	<li>Instruct patients to swallow EXALGO tablets intact, and not to cut, break, chew, crush, or dissolve the tablets (risk of potentially fatal overdose).</li>	<li>Dose may be increased using increments of 4 to 8 mg every 3 to 4 days as needed to achieve adequate analgesia.</li>	<li>Do not abruptly discontinue EXALGO in a physically-dependent patient.</li>	<li>Moderate Hepatic Impairment: Initiate treatment with 25% of the dose that would be prescribed for patients with normal hepatic function. Monitor closely for respiratory and central nervous system depression.</li>	<li>Moderate and Severe Renal Impairment: Initiate treatment in patients with moderate renal impairment with 50% and patients with severe renal impairment with 25% of the EXALGO dose that would be prescribed for patients with normal renal function. Monitor closely for respiratory and central nervous system depression.</li></ul>','Extended-release tablets: 8 mg, 12 mg, 16 mg, 32 mg (3)','<ul>	<li>Opioid non-tolerant patients </li>	<li>Significant respiratory depression</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus</li>	<li>Narrowed or obstructed gastrointestinal tract</li>	<li>Known hypersensitivity to any components including hydromorphone hydrochloride and sulfites</li></ul>','<ul>	<li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or Elderly Cachectic Debilitated Patients: Monitor closely, particularly during initiation and titration.</li>	<li>Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li>Severe Hypotension: Monitor during dose initiation and titration. Avoid use of EXALGO in patients with circulatory shock.</li>	<li>Risks of Use in Patients with Increased Intracranial Pressure, Brain, Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of EXALGO in patients with impaired consciousness or coma.</li></ul>','Most common adverse reactions (incidence >10%) are: constipation, nausea, vomiting, somnolence, headache, and dizziness.','<ul>	<li>Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue EXALGO if serotonin syndrome is suspected.</li>	<li>Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of hydromorphone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI.</li>	<li>Mixed agonist/antagonist and partial agonist opioid analgesics: Avoid use with EXALGO because they may reduce analgesic effect of EXALGO or precipitate withdrawal symptoms.</li></ul>','<ul>	<li>Pregnancy: May cause fetal harm. </li>	<li>Lactation: Not recommended. </li>	<li>Severe Hepatic Impairment: Use not recommended.</li>	<li>Severe Renal Impairment: Consider an alternate analgesic.</li></ul>',1,1,'http://www.exalgo.com/','EXALGO is an opioid agonist indicated in opioid-tolerant patients for the management of pain severe enough to require daily, around-theclock, long-term opioid treatment and for which alternative treatment options are inadequate.Patients considered opioid tolerant are those who are taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.<u>Limitations of Use</u><ul>	<li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve EXALGO for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li>	<li>EXALGO is not indicated as an as-needed (prn) analgesic.</li></ul>',1,'http://www.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147483728');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (6,'HYSINGLA','<ul>	<li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li>	<li>Daily doses of HYSINGLA ER greater than or equal to 80 mg are only for use in patients in whom tolerance to an opioid of comparable potency has been established.</li>	<li>Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals .</li>	<li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li>	<li>Instruct patients to swallow HYSINGLA ER intact, and not to crush, chew, or dissolve the tablets (risk of potentially fatal overdose).</li>	<li>Instruct patients to take tablets one at a time, with enough water to ensure complete swallowing immediately after placing in the mouth.</li>	<li>For opioid-naïve patients, initiate with 20 mg tablets orally every 24 hours.</li>	<li>To convert to HYSINGLA ER from another opioid, follow the conversion instructions to obtain an estimated dose.</li>	<li>Dose titration of HYSINGLA ER may occur every 3 to 5 days.</li>	<li><u>Patients with Severe Hepatic Impairment</u>: Initiate dosing with one half of the recommended starting dosage and titrate carefully. Monitor for respiratory depression, sedation, and hypotension.</li>	<li><u>Patients with Moderate to Severe Renal Impairment and End-Stage Renal Disease</u>: Initiate dosing at one half the recommended starting dosage and titrate carefully. Monitor for signs of respiratory depression, sedation, and ypotension.</li>	<li>Do not abruptly discontinue HYSINGLA ER in a physically dependent patient.</li></ul>','Extended-release tablets: 20, 30, 40, 60, 80, 100, and 120 mg ','<ul>	<li>Significant respiratory depression.</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment .</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus.</li>	<li>Hypersensitivity to hydrocodone or to any other components of HYSINGLA ER .</li></ul>','<ul>	<li><u>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</u>: Monitor closely, particularly during initiation and titration.</li>	<li><u>Adrenal Insufficiency</u>: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li><u>Severe Hypotension</u>: Monitor during dosage initiation and titration. Avoid use of HYSINGLA ER in patients with circulatory shock.</li>	<li><u>QTc Prolongation:</u> Avoid use in patients with congenital long QTc syndrome. In patients who develop QTc prolongation, consider reducing the dose.</li>	<li><u>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</u>: Monitor for sedation and respiratory depression. Avoid use of HYSINGLA ER in patients with circulatory shock.</li>	<li> <u>Risk of Obstruction in Patients who have Difficulty Swallowing or have Underlying GI Disorders that may Predispose them to Obstruction</u>: Consider use of an alternative analgesic.</li></ul>','Most common treatment-emergent adverse events (incidence ? 5%) are constipation, nausea, vomiting, fatigue, upper respiratory tract infection, dizziness, headache, and somnolence.','<ul>	<li><u>Serotonergic Drugs</u>: Concomitant use may result in serotonin syndrome. Discontinue HYSINGLA ER if serotonin syndrome is suspected.</li>	<li><u>Mixed Agonists/Antagonists and Partial Agonist Opioid Analgesics</u>: Avoid use with HYSINGLA ER because they may reduce analgesic effect of HYSINGLA ER or precipitate withdrawal symptoms.</li>	<li><u>Monoamine Oxidase Inhibitors (MAOIs)</u>: Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI.</li></ul>','<ul>	<li><u>Pregnancy</u>: May cause fetal harm.</li>	<li><u>Lactation</u>: Not recommended.</li></ul>',1,1,'https://hysinglaer.com/patient/home.html','<p >HYSINGLA ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</span></p><p>Limitations of Use</p><ul ><li><spanBecause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve HYSINGLA ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. </span></li>	<li>HYSINGLA ER is not indicated as an as-needed (prn) analgesic. </span></li></ul>',1,'http://app.purduepharma.com/xmlpublishing/pi.aspx?id=h');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (7,'KADIAN','<ul>	<li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li>	<li>KADIAN 100 mg and 200 mg capsules, a single dose greater than 60 mg, or a total daily dose greater than 120 mg, are only for use in patients in whom tolerance to an opioid of comparable potency has been established.</li>	<li>Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg of morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg of oral oxycodone per day, 8 mg of oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.</li>	<li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li>	<li>Instruct patients to swallow KADIAN capsules intact, or to sprinkle the capsule contents on applesauce and immediately swallow without chewing.</li>	<li>Instruct patients not to cut, break, chew, crush, or dissolve the pellets in KADIAN capsules to avoid the risk of release and absorption of potentially fatal dose of morphine.</li>	<li> For opioid-naïve patients, initiate treatment using an immediate-release morphine formulation and then convert patients to KADIAN. For opioid non-tolerant patients, initiate with a 30 mg capsule orally every 24 hours. Dosage adjustments may be made every one to two days.</li>	<li>Do not abruptly discontinue KADIAN in a physically dependent patient.</li></ul>','Extended-release capsules: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg,100 mg, 200 mg ','<ul>	<li>Significant respiratory depression.</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment.</li>	<li>Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days .</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus.</li>	<li>Hypersensitivity to morphine.</li></ul>','<ul>	<li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.</li>	<li>Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off the opioid.</li>	<li>Severe Hypotension: Monitor during dosage initiation and titration Avoid use of KADIAN in patients with circulatory shock,</li>	<li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of KADIAN in patients with impaired consciousness or coma.</li>/ul>','Most common adverse reactions (>10%): constipation, nausea, and somnolence.','<ul>	<li>Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue KADIAN if serotonin syndrome is suspected.</li>	<li>Monoamine Oxidase Inhibitors (MAOIs): Can potentiate effects of morphine. Avoid concomitant use in patients taking MAOIs or within 14 days of stopping =treatment with an MAOI.</li>	<li> Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with KADIAN because they may reduce analgesic effect of KADIAN or precipitate withdrawal symptoms.</li></ul>','<ul>	<li>Pregnancy: May cause fetal harm.</li>	<li> Lactation: Not recommended.</li></ul>',1,1,'http://www.kadian.com/','KADIAN is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.<br>Limitations of Use:<br><ul>	<li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve KADIAN for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li>	<li>KADIAN is not indicated as an as-needed (prn) analgesic.</li></ul>',1,'http://pi.actavis.com/data_stream.asp?product_group=1891&p=pi&language=E');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (8,'LEVORPHANOL',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (9,'LIDODERM',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (10,'MS CONTIN',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (11,'NUCYNTA ER','<ul>	<li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals .</li>	<li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li>	<li>Instruct patients to swallow NUCYNTA ER tablets intact, and not to cut, break, chew, crush, or dissolve the tablets (risk of potentially fatal overdose).</li>	<li>Instruct patients to take tablets one at a time, with enough water to ensure complete swallowing immediately after placing in mouth.</li>	<li>For opioid-naïve and opioid non-tolerant patients, initiate treatment with 50 mg tablet orally twice daily (approximately every 12 hours). See full prescribing information for instructions on conversion, titration, and maintenance of therapy.</li>	<li>Titrate patients with dose increases of 50 mg no more than twice daily every three days.</li>	<li>Maximum daily dose is 500 mg per day.</li>	<li>Moderate Hepatic Impairment: Initiate treatment with 50 mg NUCYNTA ER no more than every 24 hours. Do not exceed 100 mg per day. Monitor closely for respiratory and central nervous system depression.</li>	<li>Do not abruptly discontinue NUCYNTA ER in a physically-dependent patient.</li></ul>','Extended-release tablets: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg','<ul>	<li>Significant respiratory depression.</li>	<li>Acute or severe bronchial asthma.</li>	<li>Known or suspected paralytic ileus.</li>	<li>Hypersensitivity to tapentadol or to any other ingredients of the product.</li>	<li>Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days.</li></ul>','<ul>	<li>Risk of Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.</li>	<li>Serotonin Syndrome: Potentially life-threatening condition could result from concomitant serotonergic drug administration. Discontinue NUCYNTA ER if serotonin syndrome is suspected.</li>	<li>Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li>Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of NUCYNTA ER in patients with circulatory shock.</li>	<li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of NUCYNTA ER in patients with impaired consciousness or coma.</li></ul>','The most common (?10%) adverse reactions were nausea, constipation,dizziness, headache, and somnolence','Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics:<br>Avoid use with NUCYNTA ER because they may reduce analgesic effect of NUCYNTA ER or precipitate withdrawal symptoms.','<ul>	<li>Pregnancy: Based on animal data, may cause fetal harm.</li>	<li>Nursing mothers: Nursing is not recommended.</li>	<li>Severe Hepatic or Renal Impairment: Use not recommended.</li></ul>',1,1,'https://www.nucynta.com/','NUCYNTA ER is an opioid agonist indicated for the management of:<br><ul>	<li> pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</li>	<li>neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</li></ul><br>Limitations of Use:<br><ul>	<li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve NUCYNTA ER for use in patients for whom alternative treatment options (e.g., nonopioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li>	<li>NUCYNTA ER is not indicated as an as-needed (prn) analgesic. </li></ul>',1,'https://www.nucynta.com/sites/default/files/pdf/nucyntaer-pi_0.pdf');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (12,'OPANA','<ul>	<li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals .</li>	<li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li>	<li>Administer on an empty stomach, at least 1 hour prior to or 2 hours after eating.</li>	<li>OPANA ER tablets should be taken one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth.</li>	<li>For opioid-naïve and opioid non-tolerant patients, initiate treatment with 5 mg tablets orally every 12 hours.</li>	<li>To convert to OPANA ER from another opioid, use available conversion factors to obtain estimated dose.</li>	<li>Dose can be increased every 3 to 7 days, using increments of 5 to 10 mg every 12 hours (i.e., 10 to 20 mg per day).</li>	<li>Do not abruptly discontinue OPANA ER in a physically dependent patient.</li>	<li><span >Mild Hepatic Impairment</span>:  For opioid-naïve patients, initiate treatment with 5 mg and titrate slowly.  For patients on prior opioid therapy, reduce starting dose by 50% and titrate slowly.  Monitor for signs of respiratory and central nervous system depression.</li>	<li>Renal Impairment: For opioid-naïve patients, initiate treatment with 5 mg and titrate slowly.  For patients on prior opioid therapy, reduce starting dose by 50% and titrate slowly.  Monitor for signs of respiratory and central nervous system depression.</li>	<li><span >Geriatric Patients</span>: Initiate dosing with 5 mg, titrate slowly, and monitor for signs of respiratory and central nervous system depression.</li></ul>','Extended-release tablets: 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 40 mg','<ul>	<li>Significant respiratory depression.</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment.</li>	<li>Hypersensitivity to oxymorphone.</li>	<li>Moderate or severe hepatic impairment .</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus.</li></ul>','<ul>	<li><span >Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients:</span> Monitor closely, particularly during initiation and titration.</li>	<li><span >Anaphylaxis, Angioedema, and Other Hypersensitivity Reactions</span>: If symptoms occur, stop administration immediately, discontinue permanently, and do not rechallenge with any oxymorphone formulation.</li>	<li><span>Adrenal Insufficiency</span>: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li><span>Severe Hypotension</span>: Monitor during dose initiation and titration. Avoid use of OPANA ER in patients with circulatory shock.</li>	<li><span >Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury or</span><span> Impaired Consciousness</span>: Monitor for sedation and respiratory depression.  Avoid use of OPANA ER in patients with impaired consciousness or coma.</li>	<li><span >Difficulty in Swallowing: </span>Use with caution in patients who have difficulty in swallowing or have underlying GI disorders that may predispose them to obstruction.</li></ul>','Adverse reactions in ?2% of patients in placebo-controlled trials:  nausea, constipation, dizziness, somnolence, vomiting, pruritus, headache, sweating increased, dry mouth, sedation, diarrhea, insomnia, fatigue, appetite decreased, and abdominal pain.','<ul>	<li><span>Serotonergic Drugs</span>: Concomitant use may result in serotonin syndrome. Discontinue OPANA ER if serotonin syndrome is suspected.</li>	<li><span>Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</span>: Avoid use with OPANA ER because they may reduce analgesic effect of OPANA ER or precipitate withdrawal symptoms.</li>	<li><span>Monoamine Oxidase Inhibitors (MAOIs)</span>: Can potentiate the effects of oxymorphone.  Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI.</li></ul>','<ul>	<li><span>Pregnancy</span>: May cause fetal harm.</li>	<li><span>Lactation</span>: Not Recommended.</li></ul>',1,1,'http://www.opana.com/prescriber/','<p>OPANA ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</p><p><span >Limitations of Use</span></p><ul>	<li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve OPANA ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li>	<li>OPANA ER is not indicated as an as-needed (prn) analgesic.</li></ul>',1,'http://www.endo.com/File%20Library/Products/Prescribing%20Information/OpanaER_prescribing_information_newformulation.html');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (13,'ORAMORPH SR',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (14,'OXYCONTIN',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (15,'TARGIN',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (16,'ULTRAM XR',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (17,'XTAMPZA ER',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (18,'ZOHYDRO','<ul>	<li>To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain.</li>	<li>Daily doses of ZOHYDRO ER, a single dose greater than 40 mg, or a total daily dose greater than 80 mg are only for use in patients in whom tolerance to an opioid of comparable potency has been established.</li>	<li>Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.</li>	<li>Individualize dosing based on severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li>	<li>Instruct patients to swallow ZOHYDRO ER intact and not to cut, break, chew, crush, or dissolve the capsules (risk of potentially fatal overdose).</li>	<li>For opioid-naïve and opioid non-tolerant patients, initiate with 10 mg capsules orally every 12 hours.</li>	<li>To convert to ZOHYDRO ER from another opioid, use available conversion factors to obtain estimated dose.</li><li>Dose titration of ZOHYDRO ER may occur every 3 to 7 days, using increments of 10 mg every 12 hours (i.e., 20 mg per day).</li><li>Patients with Severe Hepatic Impairment: Initiate dosing with 10 mg every 12 hours and titrate carefully, while monitoring for respiratory depression, sedation, and hypotension. No adjustment in starting dose with ZOHYDRO ER is required in patients with mild or moderate hepatic impairment.</li><li>Do not abruptly discontinue ZOHYDRO ER in a physically dependent patient.</li></ul>','Extended-release capsules: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 50 mg','<ul>	<li>Significant respiratory depression</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus</li>	<li>Hypersensitivity to hydrocodone or to any other components of ZOHYDRO ER</li></ul>','<ul>	<li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.</li>	<li>Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li>Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of ZOHYDRO ER in patients with circulatory shock.</li>	<li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of ZOHYDRO ER in patients with circulatory shock.</li></ul>','Adverse reactions in ?2% of patients in placebo-controlled trials include constipation, nausea, somnolence, fatigue, headache, dizziness, dry mouth, vomiting, pruritus, abdominal pain, edema peripheral, upper respiratory tract infection, muscle spasms, urinary tract infection, back pain, and tremor.','<ul>	<li>Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue ZOHYDRO ER if serotonin syndrome is suspected.</li>	<li>Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI.</li>	<li>Mixed Agonists/Antagonists and Partial Agonist Opioid Analgesics: Avoid use with ZOHYDRO ER because they may reduce analgesic effect of ZOHYDRO ER or precipitate withdrawal symptoms.</li></ul>','<ul>	<li>Pregnancy: May cause fetal harm.</li>	<li>Lactation: Not recommended.</li></ul>',1,1,'http://www.zohydroer.com/','ZOHYDRO ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. <br>Limitations of Use :<br><ul>	<li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve ZOHYDRO ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li>	<li>ZOHYDRO ER is not indicated as an as-needed (prn) analgesic.</li></ul>',1,'http://www.zohydroer.com/downloads/ZOHYDROERFullPrescribingInformation.pdf');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (19,'NUVIGIL',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,2,'http://www.nuvigil.com/',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (20,'PROCENTRA',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,2,'https://api.drugbankplus.com/v1/us/drug_names/simple?q= AVINZA',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (21,'QUIVILANT XR',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,2,'https://www.quillivantxr-quillichewer.com/?utm_source=quillivantXR.com&utm_medium=Vanity_URL&utm_campaign=Quillivant&id=quillivantXR.com',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (22,'ZENZEDI',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,2,'http://zenzedi.com/',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (23,'CYMBALTA',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,3,'http://zenzedi.com/',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (24,'FORFIVO XL',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,3,'http://www.forfivoxl.com/',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (25,'KHEDEZLA ER',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,3,'http://www.forfivoxl.com/',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (26,'ACTIQ','<ul>	<li>Patients must require and use around-the-clock opioids when taking ACTIQ.</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.</li>	<li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li>	<li>Initial dose of ACTIQ: 200 mcg. Prescribe an initial supply of six 200 mcg ACTIQ units.</li>	<li>Individually titrate to a tolerable dose that provides adequate analgesia using single ACTIQ dosage unit per breakthrough cancer pain episode.</li>	<li>No more than two doses can be taken per breakthrough pain episode.</li>	<li>Wait at least 4 hours before treating another episode of breakthrough pain with ACTIQ.</li>	<li>Limit consumption to four or fewer units per day once successful dose is found.</li>	<li>When opioid therapy is no longer required, consider discontinuing ACTIQ along with a gradual downward of other opioids to minimize possible withdrawal effects.</li></ul>','Solid oral transmucosal lozenge: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg,and 1600 mcg','<ul>	<li>Opioid non-tolerant patients.</li>	<li>Significant respiratory depression.</li>	<li>Management of acute or postoperative pain including headache/migraines and dental pain.</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment.</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus.</li>	<li>Known hypersensitivity to fentanyl or components of ACTIQ.</li></ul>','<ul>	<li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.</li>	<li>Serotonin Syndrome: Potentially life-threatening condition could result from concomitant serotonergic drug administration. Discontinue ACTIQ if serotonin syndrome is suspected.</li>	<li>Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li>	<li>Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of ACTIQ in patients with circulatory shock.</li>	<li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of ACTIQ in patients with impaired consciousness or coma.</li></ul>','Most common (frequency ?5%): nausea, dizziness, somnolence, vomiting, asthenia,and headache, dyspnea, constipation, anxiety, confusion, depression, rash, andinsomnia.','Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid the use of mixed agonist/antagonist or partial agonist analgesics in patients who are already receiving a full opioid agonist analgesic (including ACTIQ) because they may reduce analgesic effect of ACTIQ or precipitate withdrawal symptoms.','<ul>	<li>Pregnancy: May cause fetal harm.</li>	<li>Lactation: Not recommended.</li>	<li>Renal and Hepatic Impairment: Administer ACTIQ with caution.</li></ul>',1,4,'http://www.actiq.com/','ACTIQ is an opioid agonist indicated for the management of breakthrough pain in cancer patients 16 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking, for one week or longer, around-the-clock medicine consisting of at least 60 mg of oral morphine per day, at least 25 mcg of transdermal fentanyl per hour, at least 30 mg of oral oxycodone per day, at least 8 mg of oral hydromorphone per day, at least 25 mg oral oxymorphone per day, at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids while taking ACTIQ.<br>Limitations of Use:<br><ul>	<li>Not for use in opioid non-tolerant patients.</li><li>Not for use in the management of acute or postoperative pain, including headache/ migraine or dental pain. </li><li>As a part of the TIRF REMS Access program, ACTIQ may be dispensed only to outpatients enrolled in the program.  For inpatient administration of ACTIQ (e.g., hospitals, hospices, and long-term care facilities that prescribe for inpatient use), patient and prescriber enrollment is not required.</li></ul>',1,'http://www.actiq.com/pdf/ActiqDigitalPIandMedGuide.pdf');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (27,'ABSTRAL','<ul><li>Patients must require and use around-the-clock opioids when taking ABSTRAL</li>	<li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.</li>	<li>Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.</li>	<li>Administer on the floor of the mouth directly under the tongue and allow to completely dissolve.</li>	<li>Initial dose of ABSTRAL: 100 mcg.</li>	<li>No more than two doses can be taken per breakthrough pain episode.</li>	<li>Individually titrate to a tolerable dose that provides adequate analgesia.</li><li>Wait at least 2 hours before treating another episode of breakthrough pain with ABSTRAL.</li><li>Limit consumption to treat four or fewer breakthrough pain episodes per day once a successful dose is found.</li>	<li>When opioid therapy is no longer required, consider discontinuing ABSTRAL along with a gradual downward of other opioids to minimize possible withdrawal effects.</li></ul>','Sublingual tablets: 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg and 800mcg strengths as fentanyl base.','<ul>	<li>Opioid non-tolerant patients.</li><li>Management of acute or postoperative pain including headache/migraines dental pain, or use in the emergency department.</li>	<li>Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment.</li>	<li>Known or suspected gastrointestinal obstruction, including paralytic ileus.</li><li> Known hypersensitivity to fentanyl or components of ABSTRAL</li></ul>','<ul><li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.  Serotonin Syndrome: Potentially life-threatening condition could result from concomitant serotonergic drug administration. Discontinue ABSTRAL if serotonin syndrome is suspected.</li><li>Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.</li><li>Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of ABSTRAL in patients with circulatory shock.</li><li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of ABSTRAL in patients with impaired consciousness or coma.</li></ul>','Most common (total frequency ?3%): nausea, somnolence, headache, andconstipation.','Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with ABSTRAL because they may reduce analgesic effect of ABSTRAL or precipitate withdrawal symptoms','<ul>	<li>Pregnancy: May cause fetal harm.</li>	<li>Lactation: Not Recommended.</li><li>Renal and Hepatic Impairment: Administer ABSTRAL with caution.</li></ul>',1,4,'http://www.sentynl.com/abstral','ABSTRAL is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.Patients considered opioid tolerant are those who are taking, for one week or longer, around-the-clock medicine consisting of at least 60 mg of oral morphine per day, at least 25 mcg per hour of transdermal fentanyl, at least 30 mg of oral oxycodone per day, at least 8 mg of oral hydromorphone per day, at least 25 mg oral oxymorphone per day, at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids while taking ABSTRAL.Limitations of Use:<ul><li>Not for use in opioid non-tolerant patients.</li><li>Not for use in the management of acute or postoperative pain, including headache/migraine, dental pain, or in the emergency department.</li><li>As a part of the TIRF REMS Access program, ABSTRAL may be dispensed only to outpatients enrolled in the program. For inpatient administration of ABSTRAL (e.g., hospitals, hospices, and long-term care facilities that prescribe for inpatient use), patient and prescriber enrollment is not required.</li></ul>',1,'https://static1.squarespace.com/static/564f5e8be4b0598988787d65/t/5862e97ef7e0abc3cf8c38b5/1482877328153/Abstral_Approved_Dec+2016.pdf');
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (28,'FENTORA',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,4,'http://www.sentynl.com/abstral',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (29,'LAZANDA ','<ul>	<li>Patients must require and use around-the-clock opioids when taking Lazanda.</li>	<li>Initial dose of Lazanda for all patients is 100 mcg.</li>	<li>Individually titrate to an effective dose, from 100 mcg to 200 mcg to 400 mcg, and up to a maximum of 800 mcg, that provides adequate analgesia with tolerable side effects.</li>	<li>Dose is a single spray into one nostril, a single spray into each nostril (2 sprays), or two sprays into each nostril (4 sprays); no more than four doses per 24 hours.</li>	<li>Wait at least 2 hours before treating another episode of breakthrough pain with Lazanda.</li> 	<li>During any episode, if adequate pain relief is not achieved within 30 minutes, the patient may use a rescue medication as directed by their healthcare provider.</li></ul>','Nasal spray; each spray delivers 100 mcL of solution containing either 100 mcg or 400 mcg fentanyl base. Supplied in a 5 mL bottle containing 8 sprays.','<ul><li>Opioid–non-tolerant patients.</li>	<li>Management of acute or postoperative pain including headache/migraine or dental pain.</li>	<li>Intolerance or hypersensitivity to fentanyl or components of Lazanda</li></ul>','<ul><li>Clinically significant respiratory and CNS depression can occur. Monitor patients accordingly.</li>	<li>Do not convert patients to Lazanda from other fentanyl products on a mcg per mcg basis, or substitute a Lazanda prescription for another fentanyl product, such substitution may result in fatal overdose.</li>	<li>Lazanda bottles contain medicine that can be fatal to a child. Ensure proper storage and disposal.</li>	<li>Use with other CNS depressants and potent CYP450 3A4 inhibitors may increase depressant effects including hypoventilation, hypotension, and profound sedation. Consider dosage adjustments if warranted.</li>	<li>Titrate Lazanda cautiously in patients with chronic obstructive pulmonary disease or preexisting medical conditions predisposing them to respiratory depression and in patients susceptible to intracranial effects of CO2 retention.</li></ul>','Most common (frequency ?5%): vomiting, nausea, dizziness, pyrexia, and constipation.','See Boxed Warning and Warnings and Precautions','Administer Lazanda with caution to patients with renal or hepatic impairment.',1,4,'http://www.lazanda.com/','Lazanda is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. (1)Limitations of Use:<ul><li> Lazanda may be dispensed only to patients enrolled in the TIRF REMS Access program</li></ul>',1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (30,'ONSOLIS',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,4,'http://www.bdsi.com/Onsolis.aspx',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (31,'SUBSYS',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,4,'https://www.avella.com/specialties/oncology-medications/subsys',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (37,'CAMBIA',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,6,'http://www.cambiarx.com/',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (38,'EVZIO',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,6,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (39,'GRALISE',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,6,'http://www.gralise.com/',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (40,'ONZETRA',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,6,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (41,'SOLARAZE',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,6,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (42,'TESTIM/ANDROGEL/VOGELXO',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,6,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (43,'ZEMBRACE SYMTOUCH',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,6,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (44,'ZIPSOR',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,6,'http://www.zipsor.com/',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (45,'DEMEROL',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,7,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (46,'DILAUDID',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,7,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (47,'NUCYNTA',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,7,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (48,'OXAYDO',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,7,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (49,'OXY-IR',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,7,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (50,'PRIMLEV',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,7,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (51,'TREZIX',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,7,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (52,'XTAMPZA IR',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,7,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (53,'MS-IR',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,7,NULL,NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (54,'DURAGESIC',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://www.duragesic.com/',NULL,1,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (55,'Probuphine',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,1,'https://www.avella.com/specialties/addiction-management/addiction-management-medications/probuphine',NULL,2,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (56,'PROBUPHINE',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,8,'https://www.vivitrol.com/',NULL,2,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (57,'VIVITROL',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,8,'https://bunavail.com/',NULL,2,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (58,'BUNAVAIL',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,8,'https://www.zubsolv.com/',NULL,2,NULL);
INSERT INTO `drug` (`ID`,`DRUG_NAME`,`DOSAGE_ADMINISTRATION`,`DOSAGE_FORM_STRENGTH`,`CONTRAINDICTIONS`,`WARNINGS_PRECAUSTIONS`,`ADVERSE_REACTIONS`,`DRUG_INTERACTIONS`,`USE_IN_SPECIFIC_POPULATIONS`,`AVAILABLE_AT_AVELLA`,`DRUG_CATEGORY_ID`,`SITE_URL`,`INDICATIONS_USAGE`,`DRUG_TYPE`,`PRESCRIBING_INFO`) VALUES (59,'ZUBSOLV',NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,8,'https://www.suboxone.com/',NULL,2,NULL);
